ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 13 (4) 979 -994     DOI: 10.1677/erc.1.01115
Copyright © 2006 by the Society for Endocrinology
This Article
Right arrow Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burd, C. J
Right arrow Articles by Knudsen, K. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burd, C. J
Right arrow Articles by Knudsen, K. E

REVIEW

Androgen receptor corepressors and prostate cancer

Craig J Burd1, Lisa M Morey1 and Karen E Knudsen1,2,3

1 Departments of Cell Biology,
2 Center for Environmental Genetics, and
3 UC Cancer Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0521, USA

(Requests for offprints should be addressed to K E Knudsen; Email: karen.knudsen{at}uc.edu)

The androgen receptor (AR) mediates the effects of male steroid hormones (androgens) and contributes to a wide variety of physiological and pathophysiological conditions. As such, the regulatory mechanisms governing AR activity are of high significance. Concerted effort has been placed on delineating the mechanisms that control AR activity in prostate cancer, as AR is required for survival and proliferation in this tumor type. Moreover, AR is the central therapeutic target for metastatic prostate cancers, and recurrent tumors evade therapy by restoring AR activity. It is increasingly apparent that AR cofactors which modulate receptor activity can contribute to prostate cancer growth or progression, and this has been particularly well established for AR coactivators. The present review is focused on the role of AR corepressors in governing androgen action, with a specific emphasis on their activities in prostate cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Song, H. Wang, T. L. Krebs, S.-J. Kim, and D. Danielpour
Androgenic Control of Transforming Growth Factor-{beta} Signaling in Prostate Epithelial Cells through Transcriptional Suppression of Transforming Growth Factor-{beta} Receptor II
Cancer Res., October 1, 2008; 68(19): 8173 - 8182.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.